کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5623762 1406222 2017 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
PerspectiveRecommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
ترجمه فارسی عنوان
چشم انداز توصیه های مایع مغزی و نخاعی بیومارکرهای بیماری آلزایمر در ارزیابی تشخیص اختلال شناختی خفیف
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی عصب شناسی
چکیده انگلیسی

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Alzheimer's & Dementia - Volume 13, Issue 3, March 2017, Pages 285-295
نویسندگان
, , , , , , , , , , , , ,